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PEMBINAAN VAKSIN REKOMBINAN BCG YANG MENGEKSPRESKAN 
ANTIGEN VP1 DARI ENTEROVIRUS 71 DI DALAM PEMBANGUNAN 
CALON VAKSIN 
 
ABSTRAK 
 
  Enterovirus 71 (EV71), pencetus penyebab wabak penyakit tangan, kuku dan 
mulut  (HMFD) di kalangan kanak-kanak telahpun dikenalpasti sebagai wabak yang 
diperlu dikawal segera kerana penyakit ini telah mencatatkan bilangan kes yang tinggi 
sehingga sekarang. Salah satu cara yang berkesan untuk mengawal wabak ini adalah 
dengan kaedah pemvaksinan. Oleh itu, melalui kajian ini, calon vaksin rekombinan 
BCG terhadap virus EV71 telah dibangunkan. BCG rekombinan (rBCG) yang 
mengekspreskan gen sintetik yang mengkodkan protein VP1 daripada EV71 
bercantum dengan komplek ubikuitin (UbGR) telah dihasilkan melalui teknik PCR 
himpunan setelah kedua-dua jujukan gen tersebut dioptimumkan mengikut kodon yang 
digunakan di dalam mikobakteria. Pengekspresian gen sintetik ini telah dipacu oleh 
promoter dan peptida berisyarat Ag85A daripada M.tuberculosis. Seterusnya, 
pengekspresian protein cantuman VP1-UbGRUbGR-VP1 telah dikesan melalui 
pemblotan Western pada pellet sel rekombinan menggunakan antibodi poliklonal arnab 
yang spesifik terhadap VP1 protein. Imunisasi mencit BALB/c (H-2d) dengan klon 
rBCGV1 menunjukkan adanya penghasilan antibodi yang signifikan di dalam serum 
 xviii
yang bertindakbalas dengan protein cantuman VP1-UbGRUbGR-VP1 yang ditulenkan. 
Antibodi subklas IgG2a dikenalpasti mempunyai aras yang tinggi dan signifikan 
berbanding IgG1. Splenosit yang diperolehi daripada mencit yang diimunisasi 
menunjukkan peningkatan gerakbalas proliferasi limfosit apabila dirangsang oleh 
antigen protein cantuman VP1-UbGRUbGR-VP1. Manakala, analisisa sitokin intrasel 
yang diekspres oleh sel T CD4+ dan CD8+ menunjukkan protein cantuman VP1-
UbGRUbGR-VP1 merangsang sel T CD4+ dan CD8+ untuk mengekspreskan IL-2, IFN-
γ dan IL-4. Antigen ini juga merangsang sel T CD8+ untuk mengekpreskan IL-2 dan 
IFN-γ. Analisisa sitokin ekstrasel menunjukkan aras IFN-γ yang tinggi dan signifikan 
apabila splenosit bertindakbalas dengan antigen VP1-UbGRUbGR-VP1. Secara 
keseluruhan, keputusan analisisa ujian imuniti ke atas mencit mencadangkan bahawa 
calon vaksin rBCGV1 dapat merangsang tindakbalas imuniti Th1 (T-helper 1) terhadap 
antigen yang dikaji. Keputusan-keputusan kajian ini menunjukkan rBCGV1 berpotensi 
dibangunkan sebagai vaksin dan kajian yang berterusan diperlukan bagi memastikan 
keberkesanannya. 
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CONSTRUCTION OF RECOMBINANT BCG EXPRESSING THE VP1 
ANTIGEN OF ENTEROVIRUS 71 FOR THE DEVELOPMENT OF A 
CANDIDATE VACCINE 
 
ABSTRACT 
 
Enterovirus 71 (EV71), the causativeing agent of outbreaks of hand, foot and 
mouth disease (HFMD) in children is identified as a current outbreak that needsrequire 
urgent control due to the higher high number of cases. Vaccination is one of the most 
effective methods to control the disease outbreaks. In this study, a recombinant BCG 
vaccine candidate was constructed against EV71. The recombinant BCG (rBCGV1) 
which expressesed a synthetic gene encoding theed VP1 protein of EV71 fused to 
ubiquitin complex (UbGR) which was constructed amplified using the technique of 
assembly PCR. The synthetic gene was codon technique after optimized for 
expressioning the genes into mycobacterium codon bias. The Ag85A promoter and 
signal peptide peptide sequence from M.tuberculosis drove was used to drive the 
expression and secretion of the synthetic gene expression was from M.tuberculosis. 
Hence, Tthe expression of the VP1-UbGRUbGR-VP1 fusion protein was revealed 
confirmed by Western blotting using rabbit polyclonal antibody specific to the VP1 
protein and was found in the cell recombinant pellet cell by the used ofof the 
 xx
recombinant BCG rabbit polyclonal antibody which specific to VP1 protein. Mice 
BALB/c (H-2d) that was immunized with rBCGV1 cloned showed the significant the 
ability to induce moderate antibody production in serum in BALB/c (H-2d) mice when 
sera from immunized mice were , tested against purified VP1-UbGRUbGR-VP1 purified 
fusion protein. IgG2a subclass antibody was shown to be induced at a has a 
significantly greater higher level than IgG1. Spleenocytes, which was obtained from 
rBCGV1 , immunized mice showed significant higher level of lymphocyte proliferation 
when it was stimulated with VP1-UbGRUbGR-VP1 antigencompared to control. The 
Analyses of intracellular cytokines analysis show that, which was expressed by CD4+ T 
cells and CD8+ T cells from rBCGV1 immunized mice, showed the were stimulated by 
VP1-UbGR antigen UbGR-VP1 protein to stimulated CD4+T cells to express significant 
leves of IL-2, IFN-γ and IL-4 when compared to the control. This antigen also 
stimulated CD8+T cell to express IL-2 and IFN-γ. EThe extracellular cytokine analyseis 
also showed the significantly higher levels of IFN-γ when it was stimulated with VP1-
UbGR antigencompared to control. Overall, the immunogenicity studies results 
suggested that the rBCGV1 enhanced the stimulation of immune system towards the 
Th1 (T helper 1) pathway against the studied antigen. Data from this study also 
suggested the potential of rBCGV1 to be developed as a vaccine and further studies 
must be carriedy on out to evaluate the efficacy of this candidate vaccine. 
 1  
CHAPTER 1 
 
INTRODUCTION 
 
1.0 Background 
  Enterovirus 71 (EV71) is a human Enterovirus A belonging to the Enterovirus 
genus classified in the Picornaviridae family. Since the first outbreak of EV71 in 1969, 
epidemics have occurred periodically throughout the world (Takomoto et al., 1998 and 
Hagiwara et al., 1978). The most common manifestation observed in EV71 infected 
patients is childhood exanthema or also known as hand-foot-and-mouth-disease 
(HFMD) (McMinn, 2002). EV71 can also cause neurological disease during the acute 
infection case. The most severe clinical symptoms of EV71 infection associated with 
neurological disease are aseptic meningitis, brainstem and/or cerebellar encephalitis, 
and acute flaccid paralysis (AFP). Children less than 5 years of age are vulnerable to 
EV71 infection. Neurological complications of the infection occasionally cause 
permanent paralysis or death. In the Asia Pacific region, several large outbreaks of 
EV71 epidemics have been reported in young children with fatal brainstem encephalitis 
leading to high number of fatalities (Cardosa et al., 1999, Ho et al., 1999, Komatsu et 
al., 1999 and Lum et al., 1998). In Malaysia, 34 children were reported dead during the 
EV71 outbreak in Sarawak (Cardosa et al., 1999). To control these epidemics, the 
development of effective candidate vaccines against EV71 is important (McMinn, 
2002). 
 
1.1 History of EV71 
 In 1969, the first EV71 outbreak was reported in California where the virus from 
the stool of the infants with encephalitis (Schmidt et al., 1974). EV71 associated with 
severe neurological disease cases were later isolated in New York between 1972 and 
1977 (Melnick, 1984). The first EV71 infection outside of the USA was reported in 
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Melbourne, Australia during on epidemic of aseptic meningitis between 1972 and 1973 
(Kennett et al., 1974). In 1973, the first outbreak of HFMD was observed in Sweden 
(Blomberg et al., 1974) and Japan (Hagiwara et al., 1978). 
 
 In Europe, the first reported case of EV71 occurred in Bulgaria (1975) with the 
large and severe epidemics of encephalitis and AFP ( Nagy et al. 1982 and Chumakov 
et al., 1979). 705 cases of EV71 were documented in the Bulgarian epidemic. Of that, 
83.8% of the total cases occurred in children under 5 of years age and 93% were 
paralytic cases. Children with bulbar disease (AFP) were reported dead between 10 
and 30 hours after onset of illness (Chumakov et al., 1979). 
 
 In the Asia Pacific region, EV71 cases were identified in Japan between 1973 
and 1978 with low prevalence of acute neurological disease (Hagiwara et al., 1978). In 
1985, a small outbreak of EV71 occurred in Hong Kong with several cases of AFP 
(Samuda et al., 1987). An outbreak was reported in Hubei Province, China during the 
winter of 1987 (Zheng et al., 1995). Several large epidemics and high-level endemic 
circulation have been identified since 1997 such as outbreaks in Japan (1999) 
(Komatsu, et al., 1999) and Singapore (1998) (Singh et al., 2000). In 1997, the first 
epidemic of EV71 in Malaysia occurred in Sarawak (Cardosa et al., 1999 and WHO, 
1997) and later in Peninsular Malaysia in 2001 (Lum et al., 2002). In Malaysia, 
numerous cases of HFMD, herpangina and neurological complications including 
aseptic meningitis, AFP and cerebellar ataxia were reported in young children. In 
addition, the signal feature of the epidemic in Sarawak was the syndrome of rapidly 
fatal neurogenic pulmonary oedema associated with severe brainstem encephalitis, 
that caused 34 fatalities (Cardosa et al., 1999). In Peninsular Malaysia, 4 fatal cases 
were reported associated with this syndrome (Lum et al., 2002). 
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The largest EV71 outbreak was reported in Taiwan in 1998 (Liu et al., 2000, 
Hsiung and Wang, 2000 and Ho et al., 1999) which occurred in two waves. The first 
occurred between March and July involving the whole island and the second outbreak 
occurred from September to November which was confined to the southern region. 
Approximately 3.6 million cases were reported. 1.5 million HFMD cases were estimated 
to occur during this epidemic by the National Sentinel Surveillance Network and 2.1 
million cases were asymptomatic (Ho, 2000a). Four hundred and five cases of severe 
neurological disease due to EV71 infection were documented and 78 cases were fatal 
due to neurogenic pulmonary oedema (Lum et al., 2002, McMinn et al., 2001a and 
Hsiung and Wang, 2000). 
 
 In 1999, a total of 6000 cases of HFMD occurred over a six months period from 
March until August and 29 cases progressed to severe neurological disease during the 
large outbreak in Perth, Australia (McMinn et al., 2001b). The EV71 epidemic 
continued to circulate in the Asia Pacific region during the year 2000 to 2001. This 
endemic occurred again with sporadic cases of HFMD and encephalomyelitis 
(Cardosa, 2006). Several fatal cases of encephalomyelitis were documented in 
Singapore and Peninsular Malaysia respectively in the year 2000 (Lum et al., 2002). In 
2001, numerous cases of HFMD and severe encephalomyelitis were reported in 
Southeastern Australia (McMinn, 2002).  
 
1.2 EV71 epidemiology and evolution 
A molecular epidemiological study of EV71 was done by Hagiwara et al., (1984) 
to determine the variations between EV71 strains by analyzing the capsid’s polypeptide 
and RNase T1 sequences of the virus isolated from different regions such as Japan, 
Taiwan, Bulgaria, Hungary and USA. However, these methods were insufficient to 
identify specific EV71 genetic lineages or molecular markers of virulence.  
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The 5’ untranslated region (5’ UTR) of EV71 has been studied in China by 
comparing nucleotide sequence (Zheng et al., 1995). Significant genetic variations 
between EV71 strains from different locations or time of isolation were found using this 
technique. 
 
 Brown et al.,(1995) contributed important information on the molecular 
epidemiology and evolution of EV71. The complete VP1 sequences of 113 EV71 
isolates from all over the world were compared in their study. Three independent 
genetic lineages (genogroups) of EV71 (A, B, C) were identified and were shown to 
evolved over 30 years. More than 92% of nucleotides sequences were identical within 
same genogroup whereas 78 to 83% identities were found between genogroups. The  
EV71 BrCr strain was the only strain classified into genogroup A, whereares sub-
lineages such as B1/B2 and C1/C2 were classified in genogroups B and C 
respectively. 
 
 Virus capsid protein (VP1) gene sequence of 18 strains from the 1998 
Taiwanese epidemic including all strains isolated from fatal cases showed that the 
majority of these isolates belong to a new lineage within genogroup C2 (Shih et al., 
2000). This finding was correlated with studies done by McMinn et al., 2001a.  
 
In McMinn et al., 2001a studies, the complete VP1 gene sequence of 66 EV71 
strains isolated in Malaysia, Singapore, Taiwan and Western Australia were compared. 
The study showed that two previously unidentified lineages within genogroup B (B3 
and B4) found circulating in Southeast Asia between 1997 and 2001 were also later 
confirmed as similar to the new strain found in theTaiwanese epidemic (McMinn et al., 
2001a).  
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 Genogroup B3 was shown to be predominantly in South East Asia and was 
reported as the major cause of epidemics in Sarawak (1997), Singapore (1998) and 
Western Australia (1999) (McMinn et al., 2001a). Meanwhile, genogroup B4 was found 
in a small number of cases in Singapore  (1997), Peninsular Malaysia (1997 to 1998) 
and Taiwan (1998), indicating that genogroup B4 was widespread in Asia Pacific region 
but was not predominant. In 2000, genogroup B4 became the cause of a large 
epidemic in Malaysia (Peninsular and Sarawak) and Singapore, apparently replacing 
genogroup B3 viruses (McMinn et al., 2001a).  
 
  Virus strains belonging to single lineages within genogroups B3 and C2 were 
identified during the Western Australia epidemics in 1999 (McMinn et al., 2001a). 
Nucleotide analysis, show that those of the genogroups B3 and C2 were highly similar 
with the genogroup C3 found in Sarawak (99%) and genogroup C2 found in Taiwan 
(98%) respectively.  
 
 A phylogenetic study of EV71 strains based on the VP4 gene sequence has 
been done in various countries (Shimizu et al., 1999). The results, suggest that EV71 
strains from Bulgaria and Hungary belong to genotype A-1 whilst those from Malaysia 
were identified as a genotype A -2. Strains in genotype B were more prevalent in Japan 
and Taiwan. The study also showed that the European strains were distantly related to 
recent ‘VP1-based’ genogroup B3 and B4 isolates from the Asia Pacific region 
(Shimizu et al., 1999). 
 
 
1.3 The EV71 virus 
EV71 belongs to the human Enterovirus A species and is classified under the 
enterovirus genus within the Picornaviridae family. This virion consists of a non-
enveloped capsid surrounding the core of 7.5kb single stranded RNA which has 
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positive polarity. The viral capsid is icosahedral in symmetry and is composed of 60 
identical units (protomers), each consisting of 4 structural proteins VP1, VP2, VP3 and 
VP4, respectively.  
 
The complete nucleotide sequence of the EV71 prototype strain BrCr has been 
determined. The single open reading frame (ORF) encodes a polyprotein of 2194 
amino acids and is flanked by untranslated regions (UTRs) at the 5’ and 3’ ends. A 
variable length poly-A tract is located at the terminus of the 3’ UTR. The polyprotein is 
subdivided into three regions, P1, P2 and P3, respectively. The P1 region encodes 4 
viral structural proteins named as 1A-1D (VP1-VP4). Meanwhile the P2 and P3 regions 
encode non-structural proteins known as 2A-C and 3A-D, respectively. The functions of 
the 11 individual EV71 proteins are thought to be similar to that found in poliovirus and 
other non-polio enterovirus (Brown and Pallansch, 1995). 
 
1.4  Molecular genetics of virulence in EV71 
Neurological manifestations are important aspects in EV71 infections to 
determine the neurovirulence determinants in EV71. Many studies have been done and 
were mainly focused on the VP1 gene and its product as well as the 5’UTR region. 
 
1.4.1 The VP1 gene and protein 
The VP1 gene in the EV71 genome has been identified as the most informative 
region to study the evolutionary relationships of EV71 strains. The VP1 protein has a 
highly conserved tertiary structure and has been identified as the source of virulence 
determinants for several enteroviruses (Caggana et al., 1993). The VP1 protein is also 
thought to be the major viral neutralization determinant and has a high degree of 
antigenic and genetic diversity. A deep cleft on the virion surface has been identified at 
the junction of VP1and VP2 and is thought to function as the site of virion attachment to 
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the cellular receptor (Blomberg et al., 1974). No homologous recombinations have 
been shown to occur in the VP1 gene. Thus, the VP1 gene has been found to be the 
most useful in distinguishing within and between enteroviruses serotypes (Oberste et 
al., 1999 and Oberste et al., 1995). 
 
 McMinn et al., (2001a) discovered that an EV71 strain in genogroup C2 of the 
Perth epidemic has a mutation at codon 170 causing a change from alanine to valine. 
The mutation was discovered through comparative analysis of the Perth VP1 deduced 
amino acid sequence with the VP1 consensus amino acid sequence of other EV71 
strains (genogroups A, B, C and CA16). The genogroup C2 viruses were isolated from 
children with severe neurological disease. By contrast, this substitution mutation 
(alanine-valine) in position 170 was not found in viruses obtained from the numerous 
cases of uncomplicated HFMD (McMinn et al., 2002 and McMinn, 2001a). The alanine 
residue at position 170 is a highly conserved region and exists in all EV71 and CA16 
strains. The substitution of alanine to valine increases hydrophobicity at this site and 
may change the protein conformation (Garnier et al., 1978). These data suggest that 
the mutation may be associated with the increased neurovirulence in the Perth 
epidemic (McMinn et al., 2001b). 
 
The amino acid (mutation alanine to valine) at position 170 is located in an α-
helix structure within the E-F loop in VP1, at the interface between the protomer 
subunit and on the rim of the canyon. This region that may play a role in uncoating 
following receptor binding (Garnier et al, 1978). In VP1 poliovirus protein, mutations at 
the E-F loop have been shown to alter receptor specificity by a mechanism thought to 
involve conformational change within the cleft (Wien et al., 1997 and Filman et al., 
1989). The Garnier-Osguthorpe-Robson equation for secondary structure analysis was 
used by  Garnier et al., (1978) to study the alanine to valine substitution and the results 
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suggest that the change was likely to alter the protein conformation in the E-F loop 
from an α-helix to a β-sheet. 
 
 
 
 
 
    
 
 
 
 
 
Fig 1.1: EV71 genome structure.The ORF is divided into three regions: the P1 region    
             encodes four structural proteins VP1-VP4; the P2 and P3 regions encode   
             seven non-structural proteins 2A-2C and 3A-3D, respectively. Adapted from  
             Brown and Pallansch (1995). 
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1.4.2 The 5’ UTR region 
The 5’ UTR of EV71 contain a group of conserved secondary structure element 
which is called the internal ribosome entry site (IRES). The IRES regulates enterovirus 
replication through the control of cap-independent translation of the polyprotein. Within 
the 5’ UTR of EV71, IRES-like stem loop structure has been identified (Abubakar et al., 
1999). A single nucleotide change within the poliovirus IRES resulted in a large 
alteration of the neurovirulence of the virus (Evans et al., 1985). Although, the EV71 
IRES may play an important role in neurovirulence its actual role remains unclear 
because nucleotide variation linked to neurovirulence in the EV71 IRES has not been 
identified to date. 
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CA16   lqymyvppgapkptsrdsfawqtatnpsifvkltdppaqvsvpfmspasa 
EV71 consensus lqymyvppgapkpesresfawqtatnpsivfvkltdppaqvsvpfmspasa 
 
A (BrCr)        ---------------d----p-----------ss----------------- 
 
B consensus  ---------------------------------------------------- 
 
C consensus  --------------d------------------s------------------ 
  
27M/AUS/99  --------------d------------------s------------------ 
2M/AUS/99  --------------d---------v--------s------------------ 
5M/AUS/99  --------------d---------v--------s------------------ 
6F/AUS/99  --------------d---------v--------s------------------ 
8M/AUS/99  --------------d---------v--------s------------------ 
9F/AUS/99  --------------d---------v--------s------------------ 
7F/AUS/99  --------------d------------------s------------------ 
14F/AUS/99  --------------d------------------s------------------ 
NCKU9822  --------------d------------------s------------------ 
 
Fig.Fig. 1.2: Partial alignment of VP1 deduced amino acid sequence (residue 150-200) 
of   
               the EV71 isolates from Western Australia belonging to genogroup C2. The  
               mutation alanine to valine appeared in lineage I (residue 169). Adapted from  
               McMinn, 2002. 
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1.5 Clinical symptoms of EV71 infection 
1.5.1 Hand foot and mouth disease (HFMD) and Herpangina 
HFMD have been associated most frequently with Coxsackievirus 16 (CA16), 
but also has been recognized in other enterovirus serotypes including EV71, CA5, CA9 
and CA10 (Melnick, 1984). This illness is characterized by 3 to 4 days of fever and the 
development of vesicular exanthem on the buccal mucosa, tongue, gums and palate 
and a papulove-sicular exanthema on the hand, feet and buttock (McMinn et al., 2001b 
and Komatsu et al., 1999). The rashes of HFMD due to CA16 and EV71 may differ 
(McMinn et al., 2001b and Komatsu et al., 1999). The size of the CA16 infection 
vesicles is larger than those in EV71 infections. In EV71 infection, the rash is more 
frequently papular and/or petechial, often with areas of diffuse erythema on the trunks 
and limbs. 
 
 Herpangina is an illness characterized by an abrupt onset of fever and sore 
throat, associated with the development of raised papular lesions on the mucosa of the 
anterior pillars of fauces, soft palate and uvula (Hayward et al., 1989). 
 
1.5.2 Neurological disease 
EV71 has been shown to be highly neurotropic and associated with a diverse 
range of neurological diseases such as aseptic meningitis, brainstem and/or cerebellar 
encephalitis, AFP and several post-infectious neurological syndromes (Schmidt et al., 
1974). 
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 AFP associated with EV71 infection appears to be milder with higher rates of 
complete recovery compared to AFP due to poliovirus infection ( McMinn et al., 2001b, 
Hayward et al., 1989 and Samuda et al., 1987). EV71 may induce AFP by several 
mechanisms in addition to virus-mediated destruction of the anterior horn motor 
neurons. This is reflected in the more varied clinical presentation of EV71-associated 
AFP than that seen during poliovirus infection (Alexander et al., 1994). 
 
  Brainstem encephalitis is the most severe neurological manifestation of EV71 
infection. Radioactive MR imaging and post-morterm studies indicate that the medulla 
oblongata, reticular formation, pons and midbrain structures are most frequently 
involved (Lum et al., 2002, McMinn et al., 2001b and Huang et al., 1999). Myoclonus, 
tremor, ataxia, nystagmus and cranial nerve palsies have been presented in infected 
children (Huang et al., 1999 and Wang et al., 1999). 
 
 Acute cerebellar ataxia has been associated to EV71 in many previous 
epidemics (McMinn et al., 2001b, Komatsu et al., 1999, Nagy et al., 1982 and Ishimaru 
et al., 1980). A study of MR imaging of two cases of EV71 associated cerebellar ataxia 
indicated that the acute disease was linked to inflammation of the grey matter in both 
cerebellar hemispheres and variable atrophic changes of the cerebellar cortical atrophy 
may develop upon recovery, despite complete recovery of function (McMinn et al., 
2001b). 
 
1.5.3 Neurogenic pulmonary oedema 
Neurogenic pulmonary oedema, also known as the grade III brainstem 
encephalitis has been associated with a rapid onset of cardiopulmonary failure (Huang 
et al., 1999). The fatality rate is 80% and all surviving children developed significant 
neurological sequeale during an epidemic in Taiwan(1999). Typically, children 
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develops tachycardia, tachypnoea and cyanosis between two and five days after the 
onset of fever, HFMD or herpangina (Lum et al., 2002 and Ho, 2000b).  
 
 
 
1.6 Transmission of EV71 
The mode of transmission of most enteroviruses including EV71 is by the 
faecal-oral-route via fecally contaminated materials. EV71 survive well in the external 
environment and are resistant to heat, desiccation and low temperature. The incubation 
period is characteristically 3 to 5 days between infections (Ho, 2000a). The initial sites 
of the EV71 replication are at the pharynx and terminal ilium (Fig.Figure 1.3). Virus is 
shed from the upper respitory tract for 1 to 3 weeks and from the feces for up to 38 
weeks. In an epidemic in Taiwan, the risk factors of transmission of EV71 infection 
were identified as positive serology for older sibling, children between 6 months and 3 
years of age, the number of children in the family and history of HFMD or herpangina 
(Ho, 2000a). 
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Fig.Fig. 1.3: Replication and dissemination route of EV71 infection in human body.    
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              (Adapted  
      from www.vadscorner.com/outbreak.html) 
 
 
 
 
 
 
1.7 Immunity of EV71 
1.7.1 Cell-mediated immunity 
Cell-mediated immunity is the main key component involved in host defense 
against most viruses including the enteroviruses. The main task of cell-mediated 
immunity is to kill virus-infected cells. Cytotoxic T lymphocytes CD8+ Tc (CTL) cell and 
T helper lymphocytes CD4+ Th1 cells are the main components of cell mediated 
antiviral defense (Germain, 1999). Activated Th1 cells produce a number of cytokines, 
including Interleukin 2 (IL-2), Interferon gamma (IFN-γ) and tumor necrosis factor (TNF) 
that defend against viruses either directly or indirectly. IFN-γ enhances the antiviral 
activity of macrophages. Meanwhile, IL-2 acts indirectly by assisting the recruitment of 
CTL precursors into effector population. Both IL-2 and IFN-γ activate NK (Natural Killer) 
cells, play an important role in host defense during the first days of many viral infections 
until a specific CTL response develops. Specific CTL activity arises within 3 to 4 days 
after infection, peak by 7 to 10 days, and then gradually decline. Within 7 to 10 days of 
primary infection, most viruses have been eliminated, parallelling the development of 
CTLs.  
 
 In general, CTLs recognize antigens as short fragments of proteins (8 to 10 
amino acid length) bound to the major histocompatibility complex (MHC) class I 
molecules on the cell surface. Most of these peptide epitopes are derived from the 
cytosolic degradation of proteins that are synthesized within the host cell and are 
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translocated by specific transporters from the cytosol into the endoplasmic reticulum 
where they bind to MHC class I molecules. The peptide-MHC class I complex then is 
transported, through the Golgi apparatus, to the cell surface where it is presented to 
CD8+ T lymphocytes.  
 
  
1.7.2 Humoral immunity 
Humoral immunity plays a key role in neutralizing extracellular pathogens and 
therefore is crucial for the clearance of the cytopathic viruses to prevent the reinfection. 
In general, antibodies produce in viral infection including Immunoglobulin M (IgM), IgA 
and IgG. Initially, IgM will be produced in enterovirus infections including EV71 (Sheng 
et al., 2004). Patients with X-linked agammaglobunemia (XLA) who have been infected 
by enteroviruses, have the normal profile of cell mediated immunity but are defective in 
humoral immune response (Rotbart et al., 1998). This feature leads to chronic 
enterovirus meningoencephalitis with fatal outcome. This suggests that humoral 
immunity plays an important role in the body defense against enterovirus infection. 
 
1.8 Diagnosis of EV71 infection 
The standard diagnostic approach that has been used in detecting EV71 is by 
viral isolation from patient specimens including feces, throat swabs, rectal swabs, 
cerebrospinal fluid or vesicular fluid. The specimens are inoculated into Vero, RD or 
HeLa cell cultures and the cells are incubated for a least a week. Cultures exhibiting a 
cythopathic effect are identified by microneutralization assay with antiserum against 
EV71, or by an indirect immuno-fluorescent assay with monoclonal antibody against 
BrCr strain (Shimizu et al., 1999). However, this method is time consuming and relies 
on the availability of the antisera or commercial monoclonal antibodies. 
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 To avoid these time-consuming methods, the IgM-capture enzyme linked-
immunosorbant assay (ELISA) was developed for rapid detection of EV71 infection 
(Sheng et al., 2004 and Kuo et al., 2002). The sensitivity and specificity of the assay 
were 97.7% and 93.3% (Sheng et al., 2004). Viral isolation and neutralization tests 
were used as standards. With this assay, the EV71 infection can be detected within 4 
hours.  
 
Shin et al., (2000) established the Western blot method as a diagnosis tool by 
using the VP1 capsid protein of EV71 as an antigen. Using the assay, anti-VP1 IgM 
appeared in sera of patients with a symptomatic acute infection, while anti-VP1 IgG 
was observed in sera of patients with past infection. These findings suggest that 
detecting IgG and IgM immune responses against VP1 antigens are an effective 
means of determining the different phases of EV71 infection. 
  
 Various molecular assays were also developed to detect EV71 infection, these 
included reverse transcriptase PCR (RT-PCR) and DNA microchip arrays (Shin et al., 
2003, Kuo et al., 2002 and Singh et al., 2000). RT- PCR was established by Kuo et al., 
(2002) to detect coxsackie A16 and EV71 which induces HFMD. Meanwhile, a DNA 
microchip assay for EV71 detection was developed by Shin et al., (2003) as an 
alternative diagnostic method and takes 6 hours. One hundred specimens were 
identified as positive for enteroviruses by viral culture including 67 EV71 specimens 
and these were tested using this microchip. The sensitivity and specificity of this novel 
method was 89.6% and 90.9% respectively. 
 
1.9 Control of EV71 
1.9.1 Antiviral agents 
Much work have been done to develop the promising anti-enterovirus agents 
but few are, close to commercial release and their effects on EV71 are still being 
 18  
investigated. The most promising agent and which are still under clinical trials are the 
WIN group of compound. The WIN compound, pleconaril (Rotbart et al., 1998) has 
been found to provide significant therapeutic benefit in aseptic meningitis, AFP and 
encephalitis due to many enteroviruses serotypes (Rotbart and A.D., 2001 and Starlin 
et al., 2001). Plenocaril  (3 - {3,5-methyl-4-[ [ 3-methyl-(5-isoxazolyl) propyl] phenyl]-5 
(trifluoromethyl)} - 1,2,4-oxadiazole) works by inhibiting the uncoating and the release 
of infectious viral RNA and this action inhibits the production of virions progeny. 
 The IVIG (intravenous immunoglobulin) or anti-inflammatory agent has been 
given to patients with X-linked agammaglobulinemia (XLA) and enterovirus 
meningoencephalitis. These patients fail to produce neutralizing antibody against 
enteroviruses infection. In the case of patients with chronic enteroviral 
meningoencephalitis, the strategy was successful. Enteroviral replication was 
suppressed and the cerebrospinal fluid (CSF) cultures were shown to be negative 
following treatment (Mease et al., 1981). 
 
 Even though these antiviral agents have high-level activity against EV71, but 
they still need to be further clinically evaluated. Thus, research efforts must be focused 
on the prevention of EV71 infection through the development of effective vaccines. 
 
1.9.2 Vaccines 
To prevent epidemics of EV71, the development of effective vaccine candidates 
are required for protection. Previously, a formalin-inactivated EV71 vaccine had been 
developed to control the Bulgarian epidemic in 1975, but has not been used since. 
Furthermore, no available data on the efficiency of this vaccine (Nagy et al., 1982 and 
Chumakov et al., 1979). 
 
 Cheng et al., (2001), constructed three candidate EV71 vaccines; a formalin-
inactivated vaccine, a VP1 DNA subunit vaccine and a recombinant VP1 subunit 
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protein vaccine. In challenge studies of these vaccine candidates, mice groups 
vaccinated with the inactivated virus vaccine showed 80% survival with a challenge 
dosage of 2300 LD50 virus/mice. The subunit vaccines provided protection only at a 
lower challenge dosage of 230 LD50 virus/mouse, with 40% survival for DNA vaccine 
and 80% survival for the protein recombinant vaccine. The cytokines profiles produced 
by splenocytes showed high levels of interleukin 4 (IL-4) in the inactivated virus vaccine 
group, high levels of IFN-γ and interleukin 12 (IL-12) in the DNA vaccine group and 
high levels of interleukin 10 (IL-10) and IFN-γ in the protein recombinant vaccine group. 
Overall, the inactivated virus vaccine elicited a much greater magnitude of immune 
response as compared to the subunit vaccines, including total IgG subtypes and T 
helper cell responses. These data indicated that the inactivated EV71 virus vaccine is 
the best vaccine preparation capable of fulfilling the demand of effective control, and 
that VP1 subunit vaccines remain promising strategies for the development of EV71 
vaccine. Suh et al., (2004) have optimised the micro carrier cell culture process to 
produce the inactivated EV71 virus vaccine. 
 
 The antigenic epitopes of EV71 involved in protection remain unknown. Thus, 
the identification of such epitopes is a major priority in vaccine research, as it will allow 
the development of transgenic mouse model for studies of EV71 pathogenesis and for 
the development of more effective vaccines (McMinn, 2002). 
 
1.10 Potential of recombinant BCG as a candidate vaccine against EV71    
  infection 
 
Bacille Calmette Guerin (BCG) has the potential to be developed as a vehicle 
for delivering foreign antigens by using recombinant DNA technology (Hetzel et al., 
1998 and Stover et al., 1991). This technology is based on the transfer of a selected 
gene encoding an antigen capable of inducing productive immune response, to a non-
pathogenic host, thereby making the production of an antigen safer and more efficient. 
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This approach has been used for the development of a few vaccines candidates such 
as against HIV (Human immunodeficiency virus type 1) (Aldovini and Young, 1991) 
and, malaria (Norazmi and Dale, 1997). and tuberculosis (REF?).  
 
 BCG has been selected to deliver several viral antigens in a number of studies 
because of it’s unique advantages and suitability as a multivaccine vehicle. The 
advantages include the following: 
1) BCG is the most widely used vaccine in the world, having been given to over 
2500 million people since 1948, with low incidence of serious complications. 
2) It can be administered at or any time after birth, and is unaffected by maternal 
antibodies. 
3) BCG is given as a single dose 
4) It is a potent adjuvant in experimental animals and human 
5) BCG can be administered as an oral vaccine 
6) It is the most heat stable of live vaccines 
7) It is inexpensive to produce 
 
A number of researchers have expressed viral epitopes in BCG and were able 
to induce immune response against these epitopes. Aldovini and Young (1991), found 
that rBCG which expressed the viral epitopes of HIV Gag, Pol and Env polyprotein 
under the control of heat shock protein promoter Hsp 70 can induce antibody 
production and T-cell responses against these epitopes in mice. The same approach 
also been used by Yasutomi et al., (1993) to express the antigen gig of simian 
immunodeficiency virus of rhesus monkey (SIV mac 251). Immunization with this rBCG 
elicited MHC class I-restricted, CD8+ SIV-mac251 gag-specific CTL in rhesus monkey. 
 
1.11 Ubiquitin 
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Ubiquitin is a 76 amino acid peptide involved in controlling normal protein 
intracellular turnover in the cytoplasm of eukaryotic cells. Proteins that will be degraded 
are tagged by ubiquitin molecules through covalent attachment and presented to the 
proteosome chamber. In the proteosome, the target proteins will be degraded into 
small fragments of peptides by proteolytic enzymes. The conjugation of ubiquitin has 
been shown to enhance the cell mediated immune response in vivo against the antigen 
(Rodriguez et al., 1997 and Tobery and Siliciano, 1997).  
 
In general, when the cells are infected by virus, the viral proteins will be 
conjugated to ubiquitin and transferred into proteosomes. After the degradation 
process, the small peptide fragments will be released and transported to MHC class I 
receptors on the surface of the cells. CD8+ CTLs will recognize the MHC class I 
molecule associated with the viral fragment complex and the activated CTLs will lyse 
the infected cells before the new virions are produced.  
 
 Rodriguez et al., (1997) constructed a DNA vaccine that encodes an antigen of 
the lymphocytic chorionmeningitis virus (LCMV) nucleoprotein (NP) fused to mouse 
ubiquitin. Vaccination of this DNA vaccine in mice, resulted in the enhancement of 
cytotoxic T-lymphocyte (CTL) induction and antiviral protection. However, this vaccine 
does not appear to induce antibodies. Similar findings were reported by Tobery and 
Siliciano (1997) who constructed and evaluated recombinant vaccinia vectors encoding 
an HIV-1 antigen that has been tagged to ubiquitin. 
  
 Delogu et al., (2002) successfully developed three versions of DNA vaccines 
encoding the MPT64 tuberculosis antigen fused to different variants of ubiquitin (UbG, 
UbA and UbGR). These ubiquitin proteins are known to differentially affect the 
intracellular processing of the co-expressed protein. Vaccination of the 3 DNA 
candidate vaccines (designated as UbG64, UbA64 and UbGR64) in mice gave different 
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results of the immune response. The UbA64 DNA vaccine induced a weak humoral 
response as compared to UbG64, and a mixed population of IL-4 and IFN-γ secreting 
cells. Vaccination with the UbGR64 plasmid generated a strong Th1 cell response 
(high IFN-γ and low IL-4) in the absence of any detectable humoral response. Thus, 
the expression of the antigen (MPT64) fused to UbA or UbGR molecules, shifted the 
host towards a stronger Th1 immunity response which was characterised by low 
specific antibody level and high number of IFN-γ secreting cells. Mice immunized with 
the UbGR64 DNA vaccine showed resistance to subsequent challenge with M. 
tuberculosis. Therefore, ubiquitins appear to be useful in directing towards a particular 
type of immune response and has potential for use in vaccine development. 
 
1.12 The aims of study 
The main goal of this study is to explore the use of live recombinant 
Mycobacterium bovis BCG as candidate vaccines against EV71 infection. In addition, 
the use of UbGR (Delogu et al., 2002) as a tool to enhance immune response will also 
be explored. 
 
The main aims of the study are: 
1) To generate a synthetic Mycobacterium codon optimized VP1 gene of EV71 fused to    
     ubiquitin (UbGR) by assembly PCR.  
  2) To clone the synthetic gene into a shuttle vector containing the Ag85A      
     M.tuberculosis   promoter for protein expression in BCG.   
3) To test and evaluate the immunogenicity and safety of the rBCG candidate vaccines  
       in a mouse model. 
 
(See flow chart at Fig.Figure 1.45) 
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Fig.Fig. 1.45: Flow chart for cloning, expression and animal studies. 
 
 
 
 
 
CHAPTER 2 
 
MATERIALS AND METHODS 
 
This sectionsection describes the materials and general methods used in this 
work. Specific methods are described in the respective chapters.  
 
2.12.0 Materials 
2.1.12.0.1 Mice 
Six to 8 week-old BALB/c (H-2d) female mice were obtained and housed in a 
pathogen-free environment at the animal house of the Universiti Sains Malaysia (USM), 
Health Campus, Kelantan. All animal care and experimental procedures were 
performed according to guidelines set by the Malaysian Association for Accreditation of 
Laboratory Animal Care and this work was approved by ethical committee, USM. They 
were given water and standard food pellet ad libitum.  
 
2.1.22.0.2 Bacterial strains, culture media and growth conditions 
Different E.coli strains were used for a variety of purposes during this study; 
these strains are listed in Table 2.1. Liquid and plate cultures as well as glycerol stocks 
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